Among the next generation of antipsychotics, aripiprazole is the molecule, which has been defined to have a special mode of action, which is the stabilization of the dopamine system. Different studies have found the incidence of extrapyramidal symptoms (EPS) with this antipsychotic to be very much insignificant. Studies done so far have reported the incidence of extrapyramidal side effects to be equal to that caused by placebo: here is a case report of a 19 years old female patient suffering from schizophrenic illness, who developed severe EPS in the form of marked rigidity, tremors, drooling of saliva, masked face, significant hypokinesia and difficulty in maintaining straight posture after receiving 20 mg of aripiprazole per day. This led to severe disturbance in her routine functioning and the EPS disappeared within a week after stopping the medicine and administration of anticholinergic drug.
Introduction
The first antipsychotic drug chlorpromazine was the starting point of what is rightly called revolution" in the management of psychosis-particularly schizophrenia. Many compounds followed which we now know as typical or first generation antipsychotics. Their unquestionable effect to control positive symptoms was also associated with significant side effects-mainly parkinsonism and tardive dyskinesia that made patients' life miserable. Besides, they had little effect on negative symptoms.
After the advent of novel atypical antipsychotics, which are called as second-generation antipsychotics, namely clozapine, risperidone, olanzapine, quetiapine & ziprasidone, the major problem of disturbing extrapyramidal side effects has been curtailed to a large extent. This is attributed to their affinity for receptors other than those for dopamine receptor. They are also effective against negative symptoms. They, on the other hand are not totally free of side effects like weight gain, bone marrow depression, seizures, QT prolongation etc. With higher doses, risperidone causes EPS similar to typical antipsychotics. Search for ideal antipsychotic is still on and we keep seeing newer and newer molecules in the market with different claims. One such molecule is aripiprazole which is already being claimed as third generation antipsychotic because of its supposedly different mechanism of action which is called stabilization of dopamine system (Stahl, 2000) .It is a D2 receptor partial agonist with partial agonist activity at serotonin 5HT1A receptors. Based on this "unique"mechanism of partial agonist action, it is claimed to have minimal or non-significant motor side effects (Petrie et al, 1998) .
We report a case of severe EPS with the use of aripriprazole, which lead to discontinuation of it.
Case Report:
H.K., 19 years old unmarried female presented with 6 months old psychotic illness characterized by unmanageable agitation, hallucinatory behaviour, loosening of associations, delusions of parasitosis, persecution , reference and labile mood. She was receiving alprazolam 1 mg/day, olanzapine 5 mg/day and amoxapine 100 mg/day from a general physician. After detailed work-up, diagnosis of paranoid schizophrenia (ICD-10) was made. She was put on aripiprazole 15 mg/day. Olanzapine and amoxapine were stopped and alprazolam was replaced with clonazepam 2mg per day in divided doses.
After 1 week, she reported improvement in sleep and decline in agitation but still had significant psychotic features. Dose of aripiprazole was increased to 20 mg/day and clonazepam was continued as before. Four days later she developed severe EPS. Patient had marked rigidity, resting tremors, slurred speech which was almost incomprehensible, significant hypokinesia, short sluggish gait, drooling of saliva, difficulty in maintaining straight posture & marked incapacitation. Aripiprazole was stopped .She was given inj. promethazine 50 mg i.m. and was put on trihexyphenidyl 6 mg/day. After 7 days, patient was almost completely free of the parkinsonian symptoms.
Discussion:
As per literature available so far regarding EPS related adverse events, the incidence with aripirazone has been found to be very much insignificant. This is a drug under the new class of antipsychotics: Dopamine System Stabilizer (DSS). It has been referred to as partial agonist at D 2 receptor because of which it exhibits functional dopamine antagonism at hyperactive dopamine neurons & agonistic action under hypodopaminergic condition (Burris et al., 2002) . It has been suggested that DSS do not decrease dopamine activity where dopamine level is needed (nigrostriatal pathway) and thus do not cause motor side effects (Stahl, 2001 ).
The new concept of dopamine system stabilization is considered not to induce motor side effects. Incidence of extrapyramidal adverse events with aripirazole (30mg/day) is just comparable with placebo 20% and 21% respectively (Kane et al., 2002,) . Another study compairing aripiprazole (20 mg/day, 30mg/day) with risperidone (6mg/day) has found almost similar incidence of EPS related adverse effects in both the group which was statistically not significantly different from placebo group (Potkin et al., 2003) .
Theoretical explanations seem quite encouraging but so far there are only few well designed studies to evaluate its efficacy and adverse effects. Why, the drugs which are claimed to be safe and well tolerable show different results when they come into practical use, brings out an issue which needs due consideration. The conclusions that are derived from the reports provided by the surveys and research conducted or sponsored by the pharmaceutical companies, there is every possibility of getting the results biased. Indian group of population responding differently to these molecules can be another reason for having such events. Clinical experience will certainly clear the mist surrounding the new drug and its proposed unconventional mode of action will also be tested by sound scientific research. Though it is a single case report, yet it cannot be ignored as the drug has just been introduced in the Indian market. It seems that we have still to go a long way in search of an ideal antipsychotic.
